Dr Ianthe Pitout’s research is focused on the design of splice switching antisense oligonucleotides for treating amenable genetic diseases. Ianthe's PhD research on modulating splicing factors as a therapeutic strategy for selected inherited diseases, was completed in Professors Wilton and Fletcher’s Molecular Therapies Laboratory and innovations from her PhD research have contributed to the development of a molecule that is currently undergoing early phase commercialisation to treat an inherited retinopathy. As both a PhD student and postdoctoral scientist, Ianthe has 5 years practical experience in the development of antisense oligonucleotides for translation. Currently, Ianthe is committed to developing novel therapeutic strategies for neurodegenerative diseases, in particular motor neurone disease. She has also been establishing MND cell models to evaluate novel antisense oligonucleotide therapeutics for MND.